Creon
Payments companies reported to CMS as associated with Creon. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Creon, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Creon
These are the largest totals companies reported as associated with Creon. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Girish Anand | Atlanta, GA | Gastroenterology (Internal Medicine) | $137,402.47 |
| Nathaniel Ranney | Covington, LA | Gastroenterology (Internal Medicine) | $129,161.66 |
| Abhitabh Patil | St Petersburg, FL | Gastroenterology (Internal Medicine) | $103,547.96 |
| Rogelio Silva | Oak Lawn, IL | Gastroenterology (Internal Medicine) | $98,854.30 |
| Amir Fathi | Fresno, CA | Surgical Oncology | $94,970.56 |
| David Poppers | New York, NY | Gastroenterology (Internal Medicine) | $87,671.18 |
| Christopher Chapman | Chicago, IL | Gastroenterology (Internal Medicine) | $85,643.82 |
| Cynthia Rudert | Atlanta, GA | Gastroenterology (Internal Medicine) | $74,455.20 |
| Douglas Adler | Colorado Springs, CO | Gastroenterology (Internal Medicine) | $73,241.60 |
| Zeljka Jutric | Seattle, WA | Surgery | $58,306.08 |
Prescribed Creon?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.